Abstract. Clinically, temozolomide (TMZ) is widely used in glioblastoma (GBM) treatment. However, the toxicity of TMZ may influence the quality of patient life. Thus, novel treatment options for sensitizing GBM cells to TMZ chemotherapy are necessary. Aurora-A is widely expressed in GBM and correlated with poor prognosis. It has been proven to be an effective target for gene therapy and chemotherapy. In the present study, short hairpin (sh)RNA targeting Aurora-A was employed to knockdown Aurora-A expression in GBM cells. Cell Counting Kit-8 assays, flow cytometry, colony formation assays, invasion assays and tube formation assays were used to determine the effects of Aurora-A knockdown when combined with TMZ treatment. A U251 subcutaneous cancer model was established to evaluate the efficacy of combined therapy. The results of the present study indicated that the proliferation, colony formation, invasion and angiogenesis of GBM cells were significantly inhibited by combined therapy when compared with TMZ treatment alone. In vivo results demonstrated that knockdown of Aurora-A significantly (P= 0.0084) sensitizes GBM cells to TMZ chemotherapy. The results of the present study demonstrated that knockdown of Aurora-A in GBM cells enhances TMZ sensitivity in vitro and in vivo. Therefore, Aurora-A knockdown may be a novel treatment option for decreasing TMZ toxicity and improving patient quality of life.
Introduction
Glioblastoma (GBM) is a devastating form of brain cancer with a poor median survival time, high level of resistance to current therapy and common recurrence following treatment (1) . The median survival time is 15 months, and this has improved little over the past four decades (2) . The current standard therapy for GBM includes maximum debunking surgery, radiation and treatment with the monofunctional alkylating agent temozolomide (TMZ), also referred to as Temodar ® (3) . TMZ is a chemotherapeutic DNA-methylating agent useful in the treatment of GBM (4) . DNA O6-methylguanine (O6MG) lesions created by drug exposure incorrectly pair with thymine during the first cycle of DNA replication, leading to activation of the DNA mismatch repair system (5) . The removal of the thymine opposite O6MG and subsequent reinsertion following repair resynthesis leads to cycles of futile mismatch repair (5) . This ultimately leads to DNA single-strand breaks, activation of sensors of DNA damage, the generation of DNA double-strand breaks, and delayed cell death by a combination of senescence and mitotic catastrophe (6, 7) . Despite its ability to prolong disease-free survival, the toxicity of TMZ treatment at typical doses has been proven to affect patient quality of life (8, 9) . Thus, novel treatment options for sensitizing GBM cells to TMZ chemotherapy are necessary.
Aurora-A is a serine/threonine kinase critical for centrosome duplication, spindle assembly and mitotic exit (10) (11) (12) . Human Aurora-A maps to chromosomal region 20q13.2, which is amplified in various types of cancer (12, 13) . Aurora-A is also overexpressed in terms of mRNA and protein levels in various types of cancer. Ectopic overexpression of Aurora-A has been shown to transform rodent cell lines (14, 15) , establishing it as a proto-oncogene. Aurora-A has been documented to be involved in p53 regulation as it phosphorylates p53 at Ser315, leading to its mouse double minute 2-mediated ubiquitination and subsequent proteolysis (16) . Aurora-A also drives cell cycle progression by promoting cyclin B1, Wnt, myc and other pro-proliferative signaling pathways (17) (18) (19) . Repression of Aurora-A by RNA interference delays tetraploidy, apoptosis and senescence in several types of cancer cell (20, 21) .
In the present study, it was hypothesized that knockdown of Aurora-A in GBM cells would greatly enhance their sensitivity to TMZ. Thus, in vitro short hairpin (sh)RNA targeting Aurora-A was demonstrated to be an appropriate tool to knockdown Aurora-A expression at the protein and mRNA level in U251 cells. Subsequently, Cell Counting Kit-8 (CCK8) assays, flow cytometric analysis, colony formation assays, invasion assays and tube formation assays were 
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Materials and methods
Vector construction. Plasmids were constructed through usage of the pGensil-2 parental vector (Genesil Biotechnology Co., Wuhan, China). Oligonucleotide sequences of Aurora-A-shRNA (CAC CGA TGC CCT GTC TTA CTG TCA TTC AAG AGA TGA CAG TAA GAC AGG GCA TTT TTTG) were designed by Genesil Biotechnology Co. according to a published sequence of Aurora-A-shRNA, which was shown to efficiently silence Aurora-A expression in vitro and in vivo (22) . Oligonucleotide sequences of scramble-shRNA, which had no homology with any of the mammalian sequence (CAC CGC GTA CGC GGA ATA CTT CGA TTC AAG AGA TCG AAG TAT TCC GCG TAC GTT TTTG), were designed as a negative control. The resulting recombinant plasmids were named shAurora-A or shControl (shCtrl), respectively. The two constructs were verified by DNA sequencing. Plasmids were extracted using EndoFree Plasmid Giga kits (Qiagen GmbH, Hilden, Germany) from DH5α Escherichia coli transformants and stored at -20˚C until use. The concentration was determined by measuring the A 260 /A 280 ratio using UV spectrophotometry.
Cell line and treatment. The U251 and U87-MG cell lines were obtained from American Type Culture Collection (Manassas, VA, USA). U251 and U87-MG cells were cultured in Dulbecco's Modified Eagle's Medium (DMEM) containing 10% fetal bovine serum (FBS) (Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA). All cells were maintained in a humidified atmosphere containing 5% CO 2 at 37˚C. Cell transfection was performed using FuGENE ® HP Transfection Reagent (Roche Diagnostics, Indianapolis, IN, USA) according to the manufacturer's protocol. Briefly, cells were seeded into 6-well plates at a density of 2x10 5 cells/well and cultured for 24 h to reach 70-80% confluency. A total of 2 µg plasmid was diluted in 100 µl media without serum and 5 µl FuGENE ® HP Transfection Reagent was added to the tubes containing the diluted DNA. These were subsequently mixed and the transfection complex incubated for 15 min at room temperature, before being added to the 6-well plates. Medium alone was used as blank control. Simultaneously, cells were treated with a dose of 10 µM TMZ. Cells and cell supernatant were harvested 48 h subsequent to transfection for reverse transcription-polymerase chain reaction (RT-PCR) analysis, western blotting, colony formation assays, cell proliferation assays and human umbilical vein endothelial cells (HUVEC) tube formation analysis. All treatments were performed in triplicate.
RNA extraction and RT-PCR. Total RNA was extracted from cells using TRIzol ® reagent (Invitrogen; Thermo Fisher Scientific, Inc.). RNA samples (1 µg) were subjected to reverse transcription using the Takara Primescript RT-PCR kit (Takara Bio, Inc., Otsu, Japan). The primer sequences used were as follows: Aurora-A (515 bp) 5'-GAG GCA GTG GGC TTT GG-3' (sense) and 5'-GGC AGG TAG TCC AGG GTG-3' (antisense and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (catalog no., sc-25778; dilution, 1:5,000; Santa Cruz Biotechnology, Inc., Dallas, TX, USA) at 4˚C overnight, followed by washing with TBST buffer and incubation with the following horseradish peroxidase-conjugated secondary antibodies: Goat anti-mouse immunoglobulin G (catalog no., ab97040; dilution, 1:5,000) or goat anti-rabbit (catalog no., ab191866; dilution, 1:5,000; Abcam, Cambridge, MA, USA) at 37˚C for 1 h. Bands were visualized using an enhanced chemiluminescence kit (EMD Millipore). The ratio of Aurora-A/GAPDH was calculated by using densitometry (on Image J; Version 1.0, National Institutes of Health, Bethseda, MD, USA) and values were normalized by dividing by the ratio at blank (23) .
Flow cytometric analysis (FCM)
. FCM was performed to identify apoptosis-positive cells by propidium iodide (PI) (Beyotime Institute of Biotechnology) staining. Briefly, cells were harvested with trypsin-EDTA, washed with phosphate buffered saline (PBS) twice, and pelleted (by centrifugation at 1,200 x g for 3 min at 4˚C) and suspended in 500 µl binding buffer. A total of 5 µl PI was subsequently added. Following incubation at room temperature for 15 min, analysis was performed on a FACSCalibur system (BD Biosciences, San Jose, CA, USA). Sub-G1 cells were classified as apoptosis positive cells.
Cell proliferation assay. U251 and U87-MG cells were seeded into 96 well plates at a density of 5x10 3 cells per well in 200 µl medium. Cell proliferation was monitored using the CCK8 assay (Dojindo Molecular Technologies, Inc., Kumamoto, Japan). Briefly, 10 µl CCK8 solution was added into each well, and 4 h later, the absorbance was determined at a wavelength of 450 nm. Experiments were performed in triplicate.
Colony formation assay. Transfected cells were seeded into 6-well plates at a density of 1x10 3 cells per well. After 7 days of incubation at 37˚C the cells were fixed with 100% methanol, stained with 0.05% crystal violet (Beyotime Institute of Biotechnology) and washed with PBS. The colonies were counted with an Olympus BX600 microscope in at least six randomly chosen fields. The results of three independent experiments are given.
In vitro tube formation assay. The wells of a 96-well plate were coated with ice-cold Matrigel™ (BD Biosciences). Following polymerization of the matrix at 37˚C, HUVECs isolated in the method described by Dai et al (24) were seeded onto the polymerized extracellular matrix at a density of 2x10 4 cells in 100 µl of extracellular growth medium-2 (Lonza, Walkersville, MD, USA) per well; 100 µl of the cell supernatant collected from the transfected cells was immediately added. The tube branches were photographed using a Nikon Eclipse Ti-U following 6 h of incubation. The capillary-like structures of the HUVECs were counted in three randomly selected fields. The results of three independent experiments are presented.
Invasion assay. The invasion of U251 cells was evaluated using 24-well Transwells ® (8-lm poresize; EMD Millipore), as described previously but with slight modification (25) . Briefly, the filter of the Transwell plate was coated with 50 µl Matrigel. Following Matrigel polymerization, 500 µl DMEM containing 10% FBS was placed in the lower chamber and 100 µl U251 suspension (2x10 4 cells/well; in DMEM without 10% FBS) was placed in the upper chamber. Following incubation for 48 h, cells on the lower surface were fixed in 100% methanol, stained with 0.05% crystal violet, counted in at least six randomly selected fields and photographed using an Olympus BX600 microscope.
Enzyme-linked immunosorbent assay (ELISA).
A total of 48 h after transfection, cell supernatants were collected and stored at -80˚C. The supernatant was used to measure the total levels of several cytokines using the human vascular endothelial growth factor (VEGF) ELISA kit (NeoBioscience, Shenzhen, China) according to the manufacturer's protocol.
Cat ionic liposome a n d prepa rat ion of plas mid DNA/lipoplexes. Cationic liposome was prepared as multilamellar vesicles for in vivo use as described previously (24) . Briefly, 1,2 dioleoyl-3-trimethylammonium-propoane (Avanti Polar Lipids, Inc. Alabaster, AL, USA) and cholesterol (Sigma-Aldrich; EMD Millipore) were mixed in a 1:1 molar ratio, dehydrated in round-bottom tubes using a freeze dryer (SCIENTZ-50ND; Scientz Biotechnology Co., Ltd., Ningbo, China), then rehydrated in 5% glucose solution by heating at 50˚C for 6 h. For the in vivo injection, plasmid DNA/lipoplexes were prepared immediately prior to injection by gently mixing cationic liposome with plasmid DNA at a ratio of 12.5 µg total cationic liposome to 2.5 µg plasmid DNA, resulting in a final concentration of 12.5 µg plasmid DNA per ml in a sterile solution of 5% glucose in water.
Tumor growth and treatments in vivo.
To establish a U251 subcutaneous cancer model, nude female BALB/c mice (6-8 weeks old; 18-20 g weight) were obtained from The Animal Center of Sichuan University (Chengdu, China) and housed in a 26˚C and 50% humidity-controlled facility, with a 24 h light/dark cycle and free access to food and water. A total of 5x10 6 U251 cells were injected subcutaneously into the right flank regions of nude female BALB/c mice (6-8 weeks old). After one week, when the tumors were palpable, the animals were randomly assigned to five independent groups, each group containing five mice, and subjected to systemic treatment with one of the following: shCtrl, dimethyl sulfoxide (DMSO), shAurora-A, TMZ (Sigma-Aldrich; EMD Millipore) and shAurora-A+TMZ. Plasmid DNA (2.5 µg) and cationic liposome (12.5 µg), in 100 µl of 5% glucose was injected into the mouse tail vein three times per week (on Mondays, Wednesdays and Fridays). TMZ was intraperitoneally injected once every 3 days at a dose of 200 mg/kg. Tumor diameters were measured once every three days during the treatment period. Tumor volume was estimated using the following formula: Tumor volume (mm Immunostaining. Expression of cluster of differentiation 31 (CD31) was measured with a rat anti-mouse CD31 antibody (catalog no., 550674; BD Biosciences). Tumor sections (3-5 µm) of frozen tissues were mounted on 3-aminopropyl triethoxysilane-coated glass slides. Sections were fixed with 4% paraformaldehyde and washed with PBS (pH 7.4). Endogenous peroxide was blocked with 3% H 2 O 2 for 10 min. Following PBS washes, slides were blocked with 5% normal goat serum (Beijing Zhongshan Golden Bridge Biotechnology Co., Ltd., Beijing, China) in PBS for 15 min at room temperature, followed by incubation with primary anti-CD31 (1:400) antibody in blocking solution overnight at 4˚C. All slides were subsequently incubated with a 1:200 dilution of biotin-conjugated goat anti-rat secondary antibody (catalog no., PV6004; Beijing Zhongshan Golden Bridge Biotechnology Co., Ltd.) for 15 min at 37˚C and streptavidin-biotin complex at 37˚C for 15 min. The immunoreaction was visualized using diaminobenzidine peroxide solution (Beijing Zhongshan Golden Bridge Biotechnology Co., Ltd.) and cellular nuclei were counterstained with hematoxylin (Beyotime Institute of Biotechnology). All specimens were evaluated using the Olympus BX600 microscope and Spot Fiex camera. Control samples exposed to secondary antibody alone exhibited no specific staining.
TUNEL.
To detect apoptotic cells in tumor tissue, the TUNEL assay was performed according to the manufacturer's protocol using a DeadEnd™ Fluorometric TUNEL System (Promega Corporation, Madison, WI, USA). Cell nuclei with dark green fluorescent staining were defined as TUNEL-positive. TUNEL-positive nuclei were monitored by fluorescence microscopy. To quantify TUNEL-positive cells, the number of green fluorescence-positive cells was counted in random fields at magnification, x200.
Statistical analysis. Data are expressed as the mean ± standard deviation. Statistical analysis was performed by Student's t-test for comparing two groups and by analysis of variance for multiple group comparisons with one-way analysis of variance. P<0.05 was considered to indicate a statistically significant difference. SPSS version 19 (IBM SPSS, Armonk, NY, USA) was used for all statistical analyses.
Results
Knockdown of Aurora-A sensitizes glioblastoma cells to TMZ in vitro.
The shAurora-A and shCtrl plasmids were transfected into U251 GBM cancer cells. A total of 48 h later, the cells were harvested and the expression level of Aurora-A was analyzed by western blotting and RT-PCR. As shown in Fig. 1A and B, suppression of Aurora-A expression was observed in U251 cells transfected with shAurora-A plasmid at the protein and mRNA level when compared with the control group. Subsequently, the effect of shAurora-A combined with TMZ on U251 and U87-MG cell proliferation was examined by CCK8 assay. The absorbance was determined at 0, 24, 48, 72 and 96 h following U251 and U87-MG cell transfection and treatment with TMZ. As shown in Fig. 1C and D, knockdown of Aurora-A significantly inhibits U251 (P=0.0062) and U87-MG (P=0.0072) cancer cell growth. Furthermore, TMZ treatment alone may inhibit U251 and U87-MG cancer cell growth. In addition, the U251 (P=0.0042) and U87-MG (P=0.0059) cells that were transfected with shAurora-A and treated with TMZ demonstrated significantly increased inhibition of proliferation compared with the group treated with TMZ alone. The above results indicate that knockdown of Aurora-A sensitizes GBM cells to TMZ in vitro.
Knockdown of Aurora-A increases the effects of TMZ treatment on GBM cell apoptosis and colony formation.
The quantitative assessment of sub-G1 cells by FCM was used to estimate the number of apoptotic cells. As shown in Fig. 2A and B, an increase in the sub-G1 phase population was observed by flow cytometric analysis following knockdown of Aurora-A or treatment with TMZ in U251 cell lines. Furthermore, U251 cells transfected with shAurora-A exhibited significantly increased apoptosis (P= 0.0007) compared with the TMZ-treated group. As shown in Fig. 2C and D, the inhibition of U251 cell colony formation in the shAurora-A and TMZ-treated group was measured, and compared with the shCtrl and DMSO groups, respectively. Additionally, knockdown of Aurora-A increased the inhibitive effect of TMZ treatment on U251 colony formation, compared with the group treated with TMZ alone. The results of western blot analysis shown in Fig. 2E indicated that shAurora-A (P= 0.0038) or TMZ (P= 0.0009) treatment alone significantly induced the apoptosis-associated protein p53, as well as caspase 3 expression. Furthermore, increased p53 and caspase 3 expression was observed in the shAurora-A+TMZ group. The above results indicate that knockdown of Aurora-A increases the effects of TMZ on GBM cell apoptosis and colony formation through induced p53 and caspase 3 expression.
Knockdown of Aurora-A increases the effects of TMZ treatment on GBM cell invasion and angiogenesis.
Invasion and tube formation assays were performed to determine whether there is a synergistic effect in the group knockdown of Aurora-A in U251 cells combined with TMZ treatment. As shown in Fig. 3A and B, knockdown of Aurora-A (P=0.0029) and TMZ treatment (P= 0.023) alone significantly inhibited U251 invasion, compared with the shCtrl or DMSO groups, respectively. Furthermore, fewer invasive cells were observed in the shAurora-A combined with TMZ treatment group, when compared with the TMZ only group. Subsequently, western blotting results indicated that MMP-2 and MMP-9 levels were inhibited following shAurora-A transfection (Fig. 3C) . The conditional medium from each group was used to perform the HUVEC tube formation assay. The results of the present study demonstrated that the conditional medium from the shAurora-A (P= 0.0026) or TMZ (P= 0.017) treated groups A total of 7 days later, cells were stained with 0.05% crystal violet. Colony formation assays for each group were performed. These experiments were performed in triplicate. (E) Western blot analysis was performed to measure expression of the apoptosis-associated proteins p53 and caspase-3 in each group. sh, short hairpin; TMZ, temozolomide; SD, standard deviation; DMSO, dimethyl sulfoxide; Ctrl, control.
significantly inhibited HUVEC tube formation, compared with the shCtrl or DMSO groups, respectively ( Fig. 3D and  E) . Furthermore, knockdown of Aurora-A increased the inhibition of tube formation in HUVECs, compared with the TMZ-treated group (Fig. 3D and E) . Subsequently, VEGF expression for each group was determined by ELIZA assay and decreased VEGF was observed in the shAurora-A group compared with the shCtrl group. A further decrease in VEGF expression was observed in the shAurora-A+TMZ-treated group when compared with the TMZ-treated alone group ( Fig. 3D and E) . The above results demonstrate that knockdown of Aurora-A increases the effects of TMZ treatment on GBM cell invasion and angiogenesis through the inhibition of MMP-2, MMP-9 and VEGF expression.
Knockdown of Aurora-A sensitizes GBM cells to TMZ treatment in mice.
The present study determined the effects of silencing Aurora-A on tumor growth and in mice through plasmid-based shRNA. A U251 GBM subcutaneous mouse model was used. A plasmid/liposome complex was systemically injected through the mouse tail vein, combined with or without TMZ treatment. As shown in Fig. 4A , injection of the shAurora-A/liposome complex significantly inhibited U251 subcutaneous growth, compared with the shCtrl/liposome complex group (n=5, tumor volume: shAurora-A/liposome group, 1,063.4±79.3 mm ; P= 0.0084). Furthermore, U251 tumor weight was also inhibited by combined shAurora-A/liposome complex and TMZ treatment, compared with shCtrl/liposome and DMSO groups, respectively (Fig. 4B) . The combined treatment group also displayed markedly decreased tumor weight, when compared with the TMZ only group (n=5, tumor weight: Combined group, 0.41±0.13 g vs. TMZ group 0.91±0.18 g; P=0.0067; Fig. 4B ).
To detect apoptotic cells in tumor tissue, the TUNEL assay was performed. As shown in Fig. 4C and D, an increased number of apoptotic cells was observed in the shAurora-A/liposome complex+TMZ group, compared with the shCtrl/liposome complex or DMSO groups, respectively (n=5; P=0.0052). Furthermore, there was an increased number of apoptotic cells in the shAurora-A/liposome complex+TMZ group, compared with the TMZ only group (n=5; P=0.0037). CD31 staining indicated that fewer microvessels were observed in the shAurora-A/liposome complex+TMZ group, compared with the shCtrl /liposome complex or DMSO groups, respectively (n=5; P=0.0028; Fig. 4E and F) . Furthermore, there were fewer microvessels in the shAurora-A/liposome complex+TMZ group, compared with the TMZ only group (n=5; P=0.0042; Fig. 4E and F) . The above results indicate that knockdown of Aurora-A sensitizes GBM cells to TMZ in mice by inducing apoptosis and inhibiting angiogenesis.
Discussion
The present study demonstrates that the therapeutic knockdown of Aurora-A through plasmid-based shAurora-A sensitizes GBM cells to TMZ chemotherapy in vitro and in vivo. The plasmid encoding shRNA targeting Aurora-A was proven to knockdown Aurora-A expression at the mRNA and protein level in U251 cells. Furthermore, CCK8 assays, flow cytometric analysis, colony formation assays, invasion assays and tube formation assays were used to demonstrate that knockdown of Aurora-A sensitizes GBM cells to TMZ in vitro. Notably, TMZ combined with knockdown of Aurora-A through plasmid based shAurora-A/liposome complex injection, significantly inhibited U251 subcutaneous tumor growth compared with TMZ treatment alone.
Aurora-A is widely expressed in several types of cancer and has been observed to be inversely correlated with patient prognosis (14, 15) . Previous studies indicated that Aurora-A is essential for the tumorigenic capacity and chemoresistance of colorectal cancer stem cells (26) . Thus, Aurora-A may be an effective target for gene therapy and chemotherapy. A study by Van Brocklyn et al (14) indicated that knockdown of Aurora-A in GBM by alisertib (MLN8237), a highly selective Aurora-A kinase inhibitor, extended the median survival time of mice bearing intracranial human GBM neurosphere tumor xenografts. However, whether knockdown of Aurora-A sensitizes GBM cells to TMZ treatment remains to be elucidated. In the present study, plasmid-based shRNA targeting Aurora-A was used to inhibit its expression in GBM cells. The results of the present study indicate that shAurora-A significantly inhibits the expression of Aurora-A at the mRNA and protein level. Knockdown of Aurora-A may significantly inhibit glioblastoma cell proliferation, colony formation, invasion, angiogenesis and apoptosis induction in vitro and in vivo. Further results demonstrate that inhibition of Aurora-A in U251 cells induces expression of the pro-apoptotic proteins p53 and caspase 3. Furthermore, MMP-2, MMP-9 and VEGF expression were decreased by shAurora-A.
TMZ is a widely used chemotherapeutic agent in the treatment of GBM (4) . Despite the clinical occurrence of TMZ resistance (27) , the dose of TMZ used significantly affects the patient quality of life (8, 9) . Thus, in recent years studies have focused on developing novel treatment options to sensitize GBM cells to TMZ. Several inhibitors, including KML001 and nelfinavir were proven to sensitize GBM cells to TMZ treatment (28, 29) . In the present study, TMZ treatment alone was proven to significantly inhibit glioblastoma cell proliferation, colony formation, invasion, angiogenesis, and apoptosis induction in vitro and in vivo. These observations are consistent with the results of previous studies (30, 31) . Notably, knockdown of Aurora-A in GBM cells greatly enhances TMZ sensitivity in vitro and in vivo, compared with TMZ treatment alone. This is due to the altered expression of Aurora-A regulated proteins, including p53, caspase 3, MMP-2, MMP-9 and VEGF.
The results of the present study demonstrate that knockdown of Aurora-A in GBM cells greatly enhances TMZ sensitivity in vitro and in vivo. This may present a novel treatment option for decreasing TMZ toxicity and improving patient quality of life.
